Journal
CANCER AND METASTASIS REVIEWS
Volume 27, Issue 3, Pages 459-470Publisher
SPRINGER
DOI: 10.1007/s10555-008-9130-2
Keywords
breast cancer; flow cytometry; colorectal cancer; prostate cancer; pancreatic cancer; review; cancer stem cells; biomarkers; radiation therapy; progenitors
Categories
Funding
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
Introduction The lineages assumed by stem cells during hematopoiesis can be identified by the pattern of protein markers present on the surface of cells at different stages of differentiation. Specific antibodies directed at these markers have facilitated the isolation of hematopoietic stem cells by flow cytometry. Discussion Similarly, stem cells in solid organs also can be identified using cell surface markers. In addition, solid tumors have recently been found to contain small proportions of cells that are capable of proliferation, self-renewal, and differentiation into the various cell types seen in the bulk tumor. Of particular concern, these tumor-initiating cells ( termed cancer stem cells when multipotency and self-renewal have been demonstrated) often display characteristics of treatment resistance, particularly to ionizing radiation. Thus, it is important to be able to identify these cells in order to better understand the mechanisms of resistance, and to be able to predict outcome and response to treatment. This depends, of course, on identifying markers that can be used to identify the cells, and for some solid tumors, a specific pattern of cell surface markers is emerging. In breast cancer, for example, the tumor-initiating cells have a characteristic Lin(-)CD44(+)CD24(-)/(1o) ESA(+) antigenic pattern. In cells derived from some high-grade gliomas, expression of CD133 on the cell surface appears to select for a population of tumor- initiating, treatment resistant cells. Conclusion Because multiple markers, typically examined on single cells using flow cytometry, are used routinely to identify the subpopulation of tumor- initiating cells, and because the number of these cells is small, the challenge remains to detect them in clinical samples and to determine their ability to predict outcome and/or response to treatment, the hallmarks of established biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available